Abstract

A monoclonal antibody (mAb) raised to an oestrogen-induced protein (24-kDa protein) has been suggested as a marker of women at risk of developing breast cancer. Patients with benign breast biopsies who have not developed breast cancer (benign control groups) were compared to women who had malignant breast biopsies. The benign tissue components from each group were studied. Subsequently, women with benign breast biopsies who have not developed malignancy were compared to women with benign breast biopsies who later went on to develop breast cancer. The study was carried out on formalin-fixed paraffin-embedded tissue sections. Comparison between tissue from the benign control groups and from women with breast cancer demonstrated the cytoplasmic staining in apocrine metaplasia of benign controls to be more pronounced. No staining differences were apparent between benign biopsies of patients who have not developed breast cancer and benign biopsies of those who have. We conclude that diminished expression in apocrine metaplasia of mAb to 24-kDa protein may indicate the presence of breast cancer but we have been unable to establish the role of 24-kDa protein as a marker for cancer risk.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.